EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents



EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents



Clinical Microbiology and Infection 22(6): 571.E1-4



The Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) has determined breakpoints for isavuconazole and Aspergillus and for itraconazole and Candida spp., released a new document summarizing existing and new minimum inhibitory concentration ranges for quality control strains and revised the method documents for yeast and mould susceptibility testing. This technical note is based on the EUCAST isavuconazole and itraconazole rationale documents, version 1.0 of the routine and extended internal quality control for antifungal susceptibility testing as recommended by EUCAST, and the E.Def 7.3, E.Def 9.2 and E.Def 9.3 method documents (http://www.eucast.org).

(PDF emailed within 0-6 h: $19.90)

Accession: 057677233

Download citation: RISBibTeXText

PMID: 26851656

DOI: 10.1016/j.cmi.2016.01.017



Related references

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clinical Infectious Diseases 24(2): 235-247, 1997

Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resistance Updates 16(6): 81-95, 2014

Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrobial Agents and ChemoTherapy 57(11): 5426-5431, 2014

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 178(1-2): 1-9, 2015

Antifungal susceptibility of Candida species isolated from patient with invasive fungal peritonitis and investigation on clinical breakpoints of itraconazole. Japanese Journal of Antibiotics 62(5): 415-434, 2010

Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints. Journal of Antimicrobial ChemoTherapy 65(10): 2262-2264, 2011

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clinical Microbiology Reviews 19(2): 435-447, 2006

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease 73(4): 365-368, 2012

Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades Infecciosas Y Microbiologia Clinica 35(5): 278-282, 2016

Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades Infecciosas Y Microbiología Clínica 35(5): 278-282, 2017

Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST. Journal of Antimicrobial ChemoTherapy 71(1): 3-5, 2016

Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease 77(1): 37-40, 2014

Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. Euro Surveillance 20(2): -, 2015

EUCAST breakpoints can be used to interpret direct susceptibility testing of Enterobacteriaceae from urine samples. Apmis 123(2): 152-155, 2015

Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clinical Microbiology and Infection 20(7): 698-705, 2015